Immunovant (IMVT) traded higher Monday, April 13, 2026, as market participants continued to recalibrate positions after the company’s April 2 update on two Phase 3 GO studies of batoclimab in thyroid eye disease (TED). The trials missed the prespecified primary endpoint tied to proptosis response, pushing investors to put more weight on the company’s next-generation FcRn asset, IMVT-1402, and the broader pipeline narrative rather than batoclimab’s TED prospects. (immunovant.com)

While the TED readout was a setback for batoclimab in that indication, it also clarified strategy and reduces uncertainty about where development dollars and management focus are likely to go next. With IMVT-1402 positioned as the lead value driver across multiple autoimmune indications (including Graves’ disease), traders have treated the post-data period as a reset toward the asset most associated with the longer-term bull case. (fiercebiotech.com)

Recent SEC and insider-trading headlines have also stayed in the mix, including transactions tied to equity compensation (such as sales to cover tax obligations on vested RSUs). These events don’t change the clinical outlook directly, but they can influence short-term supply/demand dynamics and keep the name active around a key news window. (stocktitan.net)

The next major IMVT catalyst is progression updates for IMVT-1402 in core autoimmune targets, particularly Graves’ disease, where investor expectations remain tied to upcoming clinical data and trial execution. Separately, the company’s next expected financial-results timing is approaching in late May to early June 2026 based on third-party earnings calendars, which can act as an additional volatility point for a clinical-stage biotech even without revenue. (marketbeat.com)